Lack of Benefit With Combination Therapy for Clostridium difficile Infection.
Limited data exist regarding combination therapy for Clostridium difficile infection (CDI). After adjusting for confounders in a cohort of patients with CDI and≥1 year old, combination therapy was not associated with significant differences in clinical outcomes, but it was associated with prolonged duration of therapy (1.22 days; 95% confidence interval, 1.03-1.44 days; P=.02). Infect Control Hosp Epidemiol 2017;38:602-605.
1Nebraska Medicine,Omaha,Nebraska.
Jessica C
JC
Njoku
1Nebraska Medicine,Omaha,Nebraska.
Trevor C
TC
Van Schooneveld
1Nebraska Medicine,Omaha,Nebraska.
Mark E
ME
Rupp
1Nebraska Medicine,Omaha,Nebraska.
Keith M
KM
Olsen
4Department of Biostatistics,University of Nebraska Medical Center,Omaha,Nebraska.
Fang
F
Qiu
4Department of Biostatistics,University of Nebraska Medical Center,Omaha,Nebraska.
Jane L
JL
Meza
3Department of Pharmacy Practice, University of Nebraska Medical Center,Omaha,Nebraska.
Elizabeth D
ED
Hermsen
D000046:Academic Medical Centers; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D016360:Clostridioides difficile / Q000187:drug effects; D003131:Combined Modality Therapy; D003967:Diarrhea / Q000188:drug therapy* / Q000382:microbiology*; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D007223:Infant; D007902:Length of Stay; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use*; D008875:Middle Aged; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014640:Vancomycin / Q000627:therapeutic use*; D055815:Young Adult
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D008795:Metronidazole; D014640:Vancomycin